Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Lyra Therapeutics, Inc. (LYRA) had Stock-Based Compensation of $0.82M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$0.18M |
|
$-8.55M |
|
-- |
|
$0.18M |
|
$9.02M |
|
$-8.84M |
|
$0.30M |
|
$-8.54M |
|
$-8.54M |
|
$-8.55M |
|
$-8.55M |
|
$-8.55M |
|
$-8.55M |
|
$-8.84M |
|
$-8.71M |
|
65.76M |
|
65.76M |
|
$-0.13 |
|
$-0.13 |
|
| Balance Sheet Financials | |
$33.91M |
|
$1.28M |
|
$22.41M |
|
$56.32M |
|
$11.47M |
|
-- |
|
$40.97M |
|
$52.44M |
|
$3.87M |
|
$3.87M |
|
$3.87M |
|
65.88M |
|
| Cash Flow Statement Financials | |
$-8.84M |
|
-- |
|
-- |
|
$42.57M |
|
$33.73M |
|
$-8.84M |
|
|
Stock-Based Compensation |
$0.82M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.96 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-4831.15% |
|
-4831.15% |
|
-- |
|
-4668.31% |
|
-4670.49% |
|
$-8.84M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-220.74% |
|
-220.74% |
|
-15.18% |
|
-220.74% |
|
$0.06 |
|
$-0.13 |
|
$-0.13 |
|